A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia

Overview

The purpose of this study is to determine whether EV06 Ophthalmic Solution is safe and effective in improving distance corrected near vision in people who have presbyopia.

Full Title of Study: “A Phase 1/2 Prospective, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution, in Improving Distance Corrected Near Vision in Subjects With Presbyopia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: March 10, 2016

Detailed Description

Study subjects who were eligible for enrollment and had provided written informed consent were randomized in a 2:1 ratio to use of either EV06 Ophthalmic Solution or Placebo Ophthalmic Solution. For the first 7 days of study product administration (Period 1: Days 1-7), subjects applied 1 drop of their assigned study product to one eye twice per day. For the next 84 days (Period 2: Days 8 – 91), if there were no unanticipated and no significant adverse events observed in the treated eye, subjects applied 1 drop of their assigned study product to both eyes twice per day.

Interventions

  • Drug: EV06 Ophthalmic Solution
  • Drug: Placebo Ophthalmic Solution

Arms, Groups and Cohorts

  • Experimental: EV06 Ophthalmic Solution
    • EV06 Ophthalmic Solution: Day 1 – 7 one drop twice per day in one eye; Day 8 – 91 one drop twice per day in both eyes.
  • Placebo Comparator: Placebo Ophthalmic Solution
    • Placebo Ophthalmic Solution (EV06 vehicle): Day 1 – 7 one drop twice per day in one eye; Day 8 – 91 one drop twice per day in both eyes.

Clinical Trial Outcome Measures

Primary Measures

  • Ocular Comfort Assessment Following Instillation at Baseline and the Day Prior to Each Study Visit
    • Time Frame: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90
    • Ocular comfort was assessed at Baseline (Day 1) and following the last dose on the day prior to each office visit. Comfort was assessed by each subject marking a visual analog scale labeled “0” (Very Comfortable), “5” (Comfortable) and “10” (Very Uncomfortable) immediately following instillation of their assigned study product to one eye (Baseline) or both eyes (Days 8 – 91). A small number indicated better comfort. No formal inferential statistics hypotheses were tested.

Participating in This Clinical Trial

Inclusion Criteria

  • 45 to 55 years of age – Distance Corrected Near Visual Acuity worse than 20/40 – Best Corrected Distance Visual Acuity of 20/20 or better in each eye – Willing and able to sign consent, following study instructions Exclusion Criteria:

  • Certain pupillary conditions – Significant astigmatism, glaucoma, diabetes, cataracts, eye surgery, ocular trauma or accommodative issues – contact lens wear within 3 days prior to and for duration of study – use of prohibited medications – participation in a clinical study within 30 days prior

Gender Eligibility: All

Minimum Age: 45 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Encore Vision, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Expert Clinical Project Lead Ophthalmology, Study Director, Encore Vision, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.